Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
Biosimilars Deals 2023
Biosimilars Deals 2024
Chris Vindurampulle
Other Podcasts
Other Updates
Our Awards
Patent Case Summaries
Patent Litigation
Paul Johns
Trade Marks

Results on DUPIXENT® (Dupilumab) from NOTUS Phase 3 COPD Trial Published in NEJM

May 20, 2024

On 20 May 2024, Regeneron and Sanofi announced the results of the NOTUS Phase 3 trial for use of  Dupixent® (dupilumab) as a maintenance treatment in adults with uncontrolled COPD and type 2 inflammation. The results were published in the New England Journal of Medicine on 21 May 2024 and reportedly demonstrate that Dupixent reduced exacerbations by 34% and improved lung function compared to placebo.   Previously, on 13 May 2024, Regeneron and Sanofi announced that the FDA accepted for priority reviewtheir sBLA for Dupixent® for adolescents with Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP).